Can gossypol be a hope for transsexual patients (male to female) before sex reassignment surgery? Just for adjusting the body to mind

Medical Hypotheses

Volumn 73, Issue 4, 2009, Pages 625-626

  Yurekli, Banu ^a   Karaca, Burcak ^a   Cetinkalp, Sevki ^a   Saygili, Fusun ^a   Uslu, Ruchan ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ESTROGEN; GOSSYPOL; PROTEIN BCL 2; SEX HORMONE;

BREAST CANCER; CEREBROVASCULAR ACCIDENT; DEPRESSION; DRUG MEGADOSE; HORMONE SUBSTITUTION; HUMAN; LETTER; MALE TO FEMALE TRANSSEXUAL; PRIORITY JOURNAL; PROLACTINOMA; PROSTATE CANCER; SEX TRANSFORMATION; STEROIDOGENESIS; THROMBOEMBOLISM; TRANSSEXUALISM;

CONTRACEPTIVE AGENTS, MALE; FEMALE; GENDER IDENTITY; GOSSYPOL; HUMANS; MALE; PREMEDICATION; PREOPERATIVE CARE; RECONSTRUCTIVE SURGICAL PROCEDURES; TRANSSEXUALISM; UROGENITAL SURGICAL PROCEDURES;

EID: 69249230729     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.06.041     Document Type: Letter

References (12)

1. Moore E., Wisniewski A., and Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 88 (2003) 3467-3473
2. Van Kesteren P., Asscheman H., Megens J., et al. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47 (1997) 337-342
3. Asscheman H., Gooren L., Assies J., et al. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexual people. Clin Endocrinol (Oxf) 28 (1988) 583-588
4. Asscheman H., Gooren L., and Eklund P. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism 38 (1989) 869-873
5. Mueller A., and Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 159 (2008) 197-202
6. Ganly I., and Taylor E.W. Breast cancer in a transsexual man receiving hormone replacement therapy. Brit J Surg 82 (1995) 341
7. Kovacs K., Stefaneanu L., Ezzat S., et al. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Archiv Pathol Lab Med 118 (1994) 562-565
8. Dorff T.B., Shazer R.L., Nepomuceno E.M., et al. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clin Genitourin Cancer 5 (2007) 344-346
9. Thurston A.V. Carcinoma of the prostate in a trranssexual. Brit J Urol 73 (1994) 217
10. Cengiz E, Karaca B, Kucukzeybek Y, et al. Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination. Mol Biol Rep 2009; March 4. (Epub ahead of print).
11. Hu X.G., Zhou H.Y., Li X.W., et al. The (+)- and (-)- gossypols potently inhibit both 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 in human and rat testes. J Steroid Biochem Mol Biol 115 (2009) 14-19
12. Mohammad R.M., Wang S., Aboukameel A., et al. Preclinical studies of a nonpeptide small-molecule inhibitor of Bcl-2 and Bcl-x(L)(-)-gossypol against diffuse large cell lymphoma. Mol Cancer Ther 4 1 (2005) 13-21